Shire Licenses Hunter Syndrome Therapy from ArmaGen Technologies
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 8 (Table of Contents)
Published: 30 Aug-2014
DOI: 10.3833/pdr.v2014.i8.2055 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
US biotech ArmaGen Technologies has secured its first major deal by partnering with Shire for the development and commercialisation of AGT-182, an enzyme replacement therapy that is potentially able to treat both the CNS and somatic manifestations of Hunter syndrome...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS